BACKGROUND AND PURPOSE: As recent studies have suggested relatively low a/b for @entity263 , the interest in hypofractionated stereotactic body radiotherapy (SBRT) for @entity263 is rising. The aim of this study is to compare dosimetric results of Cyberknife (CK) with Tomotherapy ( @entity101 ) in SBRT for @entity263 . Furthermore, the radiobiologic consequences of heterogeneous dose distribution are also analyzed. MATERIAL AND METHOD: A total of 12 cases of @entity263 previously treated with SBRT were collected. Treatments had been planned and delivered using CK. Then @entity101 plans were generated for comparison afterwards. The prescribed dose was 37.5Gy in 5 fractions. Dosimetric indices for target volumes and organs at risk (OAR) were compared. For radiobiological evaluation, generalized equivalent uniform dose (gEUD) and normal tissue complication probability (NTCP) were calculated and compared. RESULT: Both CK and @entity101 achieved target coverage while meeting OAR constraints adequately. @entity101 plans resulted in better dose homogeneity (Homogeneity index: 1.04  0.01 vs. 1.21  0.01; p=0.0022), target coverage (97.74  0.86% vs. 96.56  1.17%; p=0.0076) and conformity (new vonformity index: 1.16  0.05 vs. 1.21  0.04; p=0.0096). @entity101 was shown to predict lower late rectal @entity137 as compared to CK. Integral dose to body was also significantly lower in @entity101 plans (46.59  6.44 Gy'L vs 57.05  11.68 Gy'L; p=0.0029). CONCLUSION: Based on physical dosimetry and radiobiologic considerations, @entity101 may have advantages over CK, specifically in rectal sparing which could translate into clinical benefit of decreased late @entity137 .

Dosimetric and radiobiological comparison of Cyberknife and Tomotherapy in stereotactic body radiotherapy for XXXX .

@entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'prostate cancer'] @entity101 :: ('MESH:D006973', 'Disease') :: ['HT']
@entity263 :: (MESH:D011471,Disease) :: ['localized prostate cancer']
